Equillium Announces Three Abstracts Accepted for Presentation at the 104th Annual Meeting of the American Association of Immunologists
April 27, 2021 08:00 ET
|
Equillium
LA JOLLA, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium Announces Favorable Data From Phase 1b EQUALISE Study in Systemic Lupus Erythematosus Patients
March 30, 2021 16:01 ET
|
Equillium
Itolizumab administered subcutaneously was safe and well tolerated in patients with systemic lupus erythematosus Dose-dependent changes in pharmacodynamic markers observed with subcutaneous dosing...
Equillium Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development Update
March 24, 2021 16:05 ET
|
Equillium
Cash runway into the second half of 2023 Announced positive interim data from EQUATE study in aGVHD Multiple data and regulatory catalysts in 2021 LA JOLLA, Calif., March 24, 2021 (GLOBE...
Equillium Announces Positive Data for Itolizumab in Acute Graft-Versus-Host Disease in Two Presentations at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation
March 15, 2021 08:00 ET
|
Equillium
EQUATE acute graft-versus host disease (aGVHD) study observed rapid response and durability through day 85 EQUATE aGVHD study reported a clinically meaningful reduction in corticosteroid...
Equillium to Present at the H.C. Wainwright Global Life Sciences Conference
March 02, 2021 08:00 ET
|
Equillium
LA JOLLA, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium to Present at the SVB Leerink 10th Annual Global Healthcare Conference
February 18, 2021 08:00 ET
|
Equillium
LA JOLLA, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience
February 12, 2021 15:00 ET
|
Equillium
Higher dose cohorts demonstrated 100% overall response rate, resulting in substantial reduction in baseline corticosteroid use Dose-dependent reduction of CD6 expression on CD4+ and CD8+ T cells is...
Equillium Announces the Appointment of Katherine Xu to the Board of Directors
February 09, 2021 08:00 ET
|
Equillium
LA JOLLA, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium Announces Closing of $30 Million Registered Direct Offering
February 05, 2021 17:36 ET
|
Equillium
LA JOLLA, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium Announces Pricing of $30 Million Registered Direct Offering
February 04, 2021 08:00 ET
|
Equillium
LA JOLLA, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...